Axsome Therapeutics, Inc. (0HKF)
LSE
Closed
Aug 25, 2026
Day's Range
201.7452 wk Range
113.18Overview - 0HKF - Axsome Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
10.85B
Price / Sales (TTM)
‪320.23‬
Price / Book
‪131.26‬
EV / EBITDA
‪-62.79‬
Profitability
Gross Margin
‪19.20%‬
Profit Margin
‪-24.67%‬
Operating Margin
‪-23.41%‬
Return on Assets
‪-16.31%‬
Return on Equity
‪-245.10%‬
Ownership
Shares Outstanding
29.81M
Float
44.46M
Held by Insiders
‪15.08%‬
Held by Institutions
‪74.57%‬
Price stats
Beta
‪0.72‬
50-Day Avg
‪85.35‬
200-Day Avg
‪75.30‬
Market Cap - 0HKF - Axsome Therapeutics, Inc.
Peers - 0HKF - Axsome Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0HKFLSEAxsome Therapeutics, Inc.6.16BMarket Cap+42.31%52-week change—P/E (Trailing)‪-24.67%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0HKF - Axsome Therapeutics, Inc.
About
Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
